- Voyager Therapeutics schedules 2026 annual shareholder meeting for June 9 in virtual format.
- Shareholders will vote on election of three Class II directors: James Geraghty, Steven Hyman, Alfred Sandrock.
- Agenda includes advisory vote on named executive officer compensation.
- Meeting will also seek ratification of Ernst & Young as independent auditor for fiscal 2026.
- Investors will vote on charter amendment to raise authorized shares to 245,000,000 from 125,000,000, including common stock to 240,000,000 from 120,000,000.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voyager Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-042042), on April 10, 2026, and is solely responsible for the information contained therein.
Comments